In breast cancer, steroid hormone receptors (HRs; i.e., estrogen receptor [ER] or progesterone receptor [PR]) have been shown to be important prognostic factors and predictive markers for response to endocrine therapy in the treatment of breast cancer. This evidence concerns the gene PGR and breast cancer.